Alendronate for Effective Treatment of Male Osteoporosis : An Insight

被引:0
作者
Al Lawati, Hanan [1 ]
Al Busaidi, Sara [2 ]
Al Rawahi, Thuraiya [3 ]
Al Lawati, Abdullah [4 ]
Kifah, Ahmed [5 ]
Das, Srijit [6 ]
机构
[1] Oman Coll Hlth Sci, Dept Pharmaceut, Pharm Program, Muscat, Oman
[2] Sultan Qaboos Univ, Muscat, Oman
[3] Royal Coll Surg Ireland Bahrain, Muharraq, Bahrain
[4] Sultan Qaboos Univ Hosp, Muscat, Oman
[5] Natl Univ, Sohar, Oman
[6] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Human & Clin Anat, Muscat, Oman
关键词
Alendronate; drug; osteoporosis; male; skeletal; bone; BONE-MINERAL DENSITY; VERTEBRAL FRACTURE RISK; ZOLEDRONIC ACID; PARATHYROID-HORMONE; DOUBLE-BLIND; IN-VITRO; BISPHOSPHONATES; MEN; WOMEN; PREVALENCE;
D O I
10.2174/0113816128310838240820065324
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Osteoporosis is a major global health problem. The increase in the incidence of osteoporosis in the elderly poses a challenge to treat and also results in an economic burden for the nation. Osteoporosis has been given more importance in females, and there is an urgent need to address this disease in males. Various drugs, such as nitrogen-containing phosphonates, RANK ligand inhibitors, parathormones, and alendronate, have been used for effective treatment of osteoporosis. Alendronate (alendronic acid), a nitrogen-containing bisphosphonate that inhibits bone resorption by osteoclasts, was synthesized during the 1970s. In the present review, we discuss the pharmacokinetics, mechanism of action, adverse effects, contraindications, and toxicity monitoring of alendronate. The drug may be effectively used for the treatment of male osteoporosis in order to increase bone mineral density and prevent fractures.
引用
收藏
页码:26 / 36
页数:11
相关论文
共 141 条
[101]  
PROUGH DS, 1988, CRIT CARE CLIN, V4, P573
[102]   Addressing gaps in osteoporosis screening in kuwait using opportunistic quantitative computer tomography (QCT): a retrospective study [J].
Qadan, Laila ;
Ahmed, Adel .
ARCHIVES OF OSTEOPOROSIS, 2023, 18 (01)
[103]  
Rashki Kemmak Asma, 2020, Med J Islam Repub Iran, V34, P154, DOI 10.34171/mjiri.34.154
[104]   Osteoporosis: A still increasing prevalence [J].
Reginster, JY ;
Burlet, N .
BONE, 2006, 38 (02) :4-9
[105]   THE WORLDWIDE PROBLEM OF OSTEOPOROSIS - INSIGHTS AFFORDED BY EPIDEMIOLOGY [J].
RIGGS, BL ;
MELTON, LJ .
BONE, 1995, 17 (05) :S505-S511
[106]   INVOLUTIONAL OSTEOPOROSIS [J].
RIGGS, BL ;
MELTON, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (26) :1676-1686
[107]   Biochemical and molecular mechanisms of action of bisphosphonates [J].
Rogers, Michael J. ;
Crockett, Julie C. ;
Coxon, Fraser P. ;
Monkkonen, Jukka .
BONE, 2011, 49 (01) :34-41
[108]  
Royal Osteoporosis Society, 2021, ATYPICAL THIGH BONE
[109]   Bisphosphonates: Mode of action and pharmacology [J].
Russell, R. Graham G. .
PEDIATRICS, 2007, 119 :S150-S162
[110]   Osteoporosis among Postmenopausal Women in Jordan: A National Cross-Sectional Study [J].
Saadeh, Rami ;
Jumaa, Duaa ;
Elsalem, Lina ;
Batieha, Anwar ;
Jaddou, Hashem ;
Khader, Yousef ;
El-Khateeb, Mohammed ;
Ajlouni, Kamel ;
Allouh, Mohammed Z. .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (14)